Zelnorm Related Published Studies
Well-designed clinical trials related to Zelnorm (Tegaserod)
Influence of tegaserod on proximal gastric tone and on the perception of gastric distention in functional dyspepsia. [2011.02]
Long-term tegaserod treatment for dysmotility-like functional dyspepsia: results of two identical 1-year cohort studies. [2010.03]
Long-term tegaserod treatment for dysmotility-like functional dyspepsia: results
of two identical 1-year cohort studies. [2010]
A randomized, controlled, double-blind trial of the adjunct use of tegaserod in whole-dose or split-dose polyethylene glycol electrolyte solution for colonoscopy preparation. [2008.08]
Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. [2008.08]
Tegaserod Treatment for Dysmotility-Like Functional Dyspepsia: Results of Two Randomized, Controlled Trials. [2008.06.23]
A randomized, controlled, double-blind trial of the adjunct use of tegaserod in whole-dose or split-dose polyethylene glycol electrolyte solution for colonoscopy preparation. [2008.05.27]
Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. [2008.05]
Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome. [2007.08]
Effect of tegaserod on recto-sigmoid tonic and phasic activity in constipation-predominant irritable bowel syndrome. [2007.08]
Economic Evaluation of Tegaserod vs. Placebo in the Treatment of Patients with Irritable Bowel Syndrome: An Analysis of the TENOR Study. [2007.07]
Significant enhancement of esophageal pre-epithelial defense by tegaserod: implications for an esophagoprotective effect. [2007.04]
Efficacy of tegaserod for functional constipation in Chinese subjects: a randomized double-blind controlled trial in a single centre. [2007.02.15]
A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation. [2007.02.07]
Efficacy of tegaserod in chronic constipation in men. [2007.02]
Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation. [2006.11]
The effects of tegaserod on oesophageal function and bolus transport in healthy volunteers: studies using concurrent high-resolution manometry and videofluoroscopy. [2006.10.01]
Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity. [2006.04]
Use of tegaserod along with polyethylene glycol electrolyte solution for colonoscopy bowel preparation: a prospective, randomized, double-blind, placebo-controlled study. [2006.03.01]
Effect of tegaserod on gut transit in male and female subjects. [2005.12]
A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. [2005.12]
Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation. [2005.09.01]
Omeprazole delays gastric emptying in healthy volunteers: an effect prevented by tegaserod. [2005.07.01]
Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. [2005.02]
Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. [2004.09]
The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study. [2004.07.15]
Systematic review: incidence of abdominal/pelvic surgery amongst patients using tegaserod in randomized controlled trials. [2004.02.01]
A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. [2004.02]
Influence of tegaserod on proximal gastric tone and on the perception of gastric distension. [2003.11.15]
An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. [2003.05]
Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. [2003.02.15]
A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. [2002.11]
Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. [2002.09]
Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms. [2002.05]
Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. [2001.11]
The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects. [2001.10]
Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. [2001.10]
Tegaserod coadministration does not alter the pharmacokinetics of theophylline in healthy subjects. [2001.09]
Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919). [2001.03]
The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. [2000.11]
Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. [2000.03]
Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919). [1999.09]
Well-designed clinical trials possibly related to Zelnorm (Tegaserod)
The shortcomings of clinical trials assessing the efficacy of probiotics in
irritable bowel syndrome. [2012]
Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT(4) agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial. [2007.10]
Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT(4) agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial. [2007.05.21]
Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective. [2006.07.15]
Evaluation of drug treatment in irritable bowel syndrome. [2003.10]
Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration. [1999.05]
Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit. [1997.11]
First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine4 receptor agonist. [1997.03]
Other research related to Zelnorm (Tegaserod)
Influence of tegaserod on proximal gastric tone and on the perception of gastric
distention in functional dyspepsia. [2011]
Treatment of acute colonic pseudo-obstruction with tegaserod. [2010.06]
Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study. [2010.06]
Safety and efficacy of tegaserod therapy in patients with irritable bowel syndrome or chronic constipation. [2010.01]
Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats. [2009.11]
Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study. [2009.09]
Patients treated by tegaserod for irritable bowel syndrome with constipation showed significant improvement in fibromyalgia symptoms. A pilot study. [2009.09]
Direct-to-consumer and physician promotion of tegaserod correlated with physician visits, diagnoses, and prescriptions. [2009.08]
Effects of tegaserod and erythromycin in upper gut dysmotility: a comparative study. [2009.07]
How effective is tegaserod for the treatment of female patients with mixed subtype IBS? [2008.10.14]
Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study. [2008.09.02]
Tegaserod in patients with mechanical sensitivity and overlapping symptoms of functional heartburn and functional dyspepsia. [2008.08]
In vitro and in vivo evaluation of tegaserod maleate pH-dependent tablets. [2008.05]
Sensory signalling effects of tegaserod in patients with irritable bowel syndrome with constipation. [2008.02]
Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. [2008.01.01]
Tegaserod use in children: a single-center experience. [2008.01]
Clinical trial: effects of tegaserod on gastric motor and sensory function in patients with functional dyspepsia. [2007.11.15]
Sensory signalling effects of tegaserod in patients with irritable bowel syndrome with constipation. [2007.11.14]
The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients. [2007.11]
Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. [2007.10.17]
Experimental pancreatitis disturbs gastrointestinal and colonic motility in mice: effect of the prokinetic agent tegaserod. [2007.10]
Clinical trial: effects of tegaserod on gastric motor and sensory function in patients with functional dyspepsia. [2007.09.24]
A randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation. [2007.09]
Characteristics, diagnostic and symptom profile of patients receiving tegaserod in routine clinical practice in Canada. [2007.09]
Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation. [2007.08]
A Randomized, Multicenter Comparison of Polyethylene Glycol Laxative and Tegaserod in Treatment of Patients With Chronic Constipation. [2007.06.15]
[Tegaserod in treatment of women with irritable bowel syndrome] [2007.06.04]
Tegaserod for dyspepsia and reflux symptoms in patients with chronic constipation: an exploratory open-label study. [2007.06]
A clinical audit of the efficacy of tegaserod as a prokinetic agent in the intensive care unit. [2007.06]
Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation. [2007.05.24]
Effect of Tegaserod on Recto-Sigmoid Tonic and Phasic Activity in Constipation-Predominant Irritable Bowel Syndrome. [2007.05.23]
Pharmacokinetics and in vitro effects of tegaserod, a serotonin 5-hydroxytryptamine 4 (5-HT4) receptor agonist with prokinetic activity in horses. [2007.03]
Tegaserod for constipation-predominant irritable bowel syndrome. [2007.02]
Tegaserod for treating chronic constipation in elderly patients. [2007.02]
Tegaserod for Treating Chronic Constipation in Elderly Patients (February). [2007.01.16]
Tegaserod in constipation associated with Parkinson disease. [2007.01]
An observational study of cholecystectomy in patients receiving tegaserod. [2007]
Efficacy of Tegaserod in Chronic Constipation in Men. [2006.12.11]
Double-blind, randomized, placebo-controlled study to evaluate the effects of tegaserod on gastric motor, sensory and myoelectric function in healthy volunteers. [2006.09.01]
Modulation of intestinal gas dynamics in healthy human volunteers by the 5-HT receptor agonist tegaserod. [2006.08]
[Serotonin transporter gene polymorphisms in irritable bowel syndrome and their impact on tegaserod treatment] [2006.07]
Effects of tegaserod on bile composition and hepatic secretion in Richardson ground squirrels on an enriched cholesterol diet. [2006.06.22]
Safety and tolerability of tegaserod in patients with chronic constipation: pooled data from two phase III studies. [2006.05]
The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome. [2006.03]
Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. [2006.01.01]
Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease. [2006.01]
[Pharmacoeconomics and outcome research on Irritable Bowel Syndrome review of findings using Tegaserod] [2006.01]
Omeprazole-induced slowing of gastrointestinal transit in mice can be countered with tegaserod. [2005.07.04]
The use of tegaserod in critically ill patients with impaired gastric motility. [2005.06]
Tegaserod-associated ischemic colitis. [2005.04]
Tegaserod treatment for IBS: a model of indirect costs. [2005.04]
|
